Last reviewed · How we verify
DE-130A/DE-130A
DE-130A/DE-130A is a Prostaglandin analog or intraocular pressure-lowering agent Small molecule drug developed by Santen SAS. It is currently in Phase 3 development for Glaucoma, Ocular hypertension. Also known as: Catiolanze®.
DE-130A is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension.
DE-130A is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension. Used for Glaucoma, Ocular hypertension.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DE-130A/DE-130A |
|---|---|
| Also known as | Catiolanze® |
| Sponsor | Santen SAS |
| Drug class | Prostaglandin analog or intraocular pressure-lowering agent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
DE-130A is a prostaglandin analog or related compound formulated for ocular delivery to lower intraocular pressure by enhancing uveoscleral outflow of aqueous humor. The drug is being developed by Santen SAS, a company specializing in ophthalmology, and is in Phase 3 clinical trials for glaucoma management.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Increased iris pigmentation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DE-130A/DE-130A CI brief — competitive landscape report
- DE-130A/DE-130A updates RSS · CI watch RSS
- Santen SAS portfolio CI
Frequently asked questions about DE-130A/DE-130A
What is DE-130A/DE-130A?
How does DE-130A/DE-130A work?
What is DE-130A/DE-130A used for?
Who makes DE-130A/DE-130A?
Is DE-130A/DE-130A also known as anything else?
What drug class is DE-130A/DE-130A in?
What development phase is DE-130A/DE-130A in?
What are the side effects of DE-130A/DE-130A?
Related
- Drug class: All Prostaglandin analog or intraocular pressure-lowering agent drugs
- Manufacturer: Santen SAS — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: Catiolanze®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing